ROBIN PARIHAR to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications ROBIN PARIHAR has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.146
-
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 2004 Aug 01; 10(15):5027-37.
Score: 0.044
-
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002 Oct; 110(7):983-92.
Score: 0.039
-
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-? production. J Immunol. 2011 Mar 15; 186(6):3401-9.
Score: 0.017
-
Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol. 2006 Jul 01; 177(1):120-9.
Score: 0.013
-
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006 Jan 01; 66(1):517-26.
Score: 0.012
-
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005 Aug 01; 175(3):1619-27.
Score: 0.012
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.010